Orexo AB A (C5G.F) is classified as Not Halal (Non-Compliant) according to AAOIFI Shariah screening standards. This assessment is based on business activity screening and financial ratio analysis using the AAOIFI methodology.
Business Activity Screen
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Result
Pass
Reason
The sector "Healthcare" and industry "Drug Manufacturers - Specialty & Generic" are not in the excluded categories.
Financial Ratios
Debt Ratio
Value: 0.6% | Threshold: 30% | Result: Pass
Cash & Interest-bearing Securities Ratio
Value: 20.0% | Threshold: 30% | Result: Pass
Non-Permissible Income Ratio
Value: 15.8% | Threshold: 5% | Result: Fail
Dividend Purification
Purification percentage: 15.77%.Based on the company's financial statements, approximately 15.77% of dividend income comes from non-permissible sources; this is the share many investors donate to purify it. This is derived from identified interest income (15.77% of total income). Some scholars may differ on the exact calculation method.
About Orexo AB A
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabact UBT for the treatment of diagnosis of Helicobacter pylori. The company is developing Izipry for opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; OX390 for overdoses caused by a combination of life-threatening illicit drugs; OX125 for opioid overdose with powder-based nalmefene; OX472 for intranasal formulation of semaglutide, a GLP-1 receptor agonist, developed using proprietary AmorphOX technology; and develops thermostable and needle-free mucosal vaccines. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
Based on the company's financial statements, approximately 15.77% of dividend income comes from non-permissible sources; this is the share many investors donate to purify it. This is derived from identified interest income (15.77% of total income). Some scholars may differ on the exact calculation method.
Uses quarterly data
About Orexo AB A
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabact UBT for the treatment of diagnosis of Helicobacter pylori. The company is developing Izipry for opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; OX390 for overdoses caused by a combination of life-threatening illicit drugs; OX125 for opioid overdose with powder-based nalmefene; OX472 for intranasal formulation of semaglutide, a GLP-1 receptor agonist, developed using proprietary AmorphOX technology; and develops thermostable and needle-free mucosal vaccines. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
SwedenFRAHealthcare
Screened using AAOIFI Standard No. 21 on October 27, 2026. Financial ratios compared against market capitalization. Different methodologies may produce different results. Learn how we screen.
Screened using AAOIFI Shariah Standard No. 21 (3 ratios). Debt and interest-bearing deposits must each be under 30% of market capitalization, and non-permissible income under 5% of total income. This screening is for educational purposes only and does not constitute a fatwa or religious ruling. Results are based on publicly available financial data and automated analysis. Users should consult qualified Islamic scholars and financial advisors for personal investment decisions. Financial data may be delayed or incomplete. Past compliance does not guarantee future status.
Verdict history
Free with an account.
No verdict changes recorded since first screened on Oct 27, 2026. We started recording changes on Oct 27, 2026.
Dates are when Mizaan recorded the change. Tracked and watched stocks are re-checked weekly; other stocks are re-screened on demand.
Get More on the Mizaan App
Live charts, market cap, financials, AI business analysis, portfolio tracking, and compliance alerts — all on your phone.
Frequently Asked Questions
According to AAOIFI Shariah screening standards, Orexo AB A (C5G.F) is currently classified as Not Halal (Non-Compliant). This is based on both business activity and financial ratio screening.
Identified interest income is 15.8% of Orexo AB A's total income. AAOIFI standards require non-permissible income to be below 5%.
C5G.F is screened using AAOIFI Standard No. 21, which involves two checks: business activity screening (ensuring the company's core business is permissible in Islam) and financial ratio screening (checking debt, interest income, and cash ratios against defined thresholds). AAOIFI is the most widely recognized standard for Islamic finance.
Orexo AB A's compliance status is reviewed whenever new financial data becomes available, typically after quarterly or annual earnings reports. Market cap changes can also affect financial ratio screening results. Mizaan refreshes screening data periodically to reflect the latest filings.
Watch C5G.F free with a Mizaan account. Watched stocks are re-checked weekly, and any verdict change is dated in the verdict history on this page. Premium members also get an alert when it changes.
Approximately 15.77% of dividend income from Orexo AB A comes from non-permissible sources such as interest income. Many investors purify that share by donating it to charity; scholars differ on the details, so check with one you trust.
Yes, Zakat is generally due on stock holdings. The calculation depends on your school of thought (madhab) and whether you hold shares for trading or long-term investment. Use Mizaan's Zakat calculator to compute your obligation based on your specific madhab and holding intent.
According to AAOIFI Shariah screening standards, Orexo AB A (C5G.F) is currently classified as Not Halal (Non-Compliant). This is based on both business activity and financial ratio screening.
Does Orexo AB A have any interest income?
Identified interest income is 15.8% of Orexo AB A's total income. AAOIFI standards require non-permissible income to be below 5%.
What guidelines are used to determine if C5G.F stock is Shariah-compliant?
C5G.F is screened using AAOIFI Standard No. 21, which involves two checks: business activity screening (ensuring the company's core business is permissible in Islam) and financial ratio screening (checking debt, interest income, and cash ratios against defined thresholds). AAOIFI is the most widely recognized standard for Islamic finance.
How often is Orexo AB A stock reviewed for Shariah compliance?
Orexo AB A's compliance status is reviewed whenever new financial data becomes available, typically after quarterly or annual earnings reports. Market cap changes can also affect financial ratio screening results. Mizaan refreshes screening data periodically to reflect the latest filings.
How can I stay updated on Orexo AB A's compliance status?
Watch C5G.F free with a Mizaan account. Watched stocks are re-checked weekly, and any verdict change is dated in the verdict history on this page. Premium members also get an alert when it changes.
Are dividends from Orexo AB A stock considered halal?
Approximately 15.77% of dividend income from Orexo AB A comes from non-permissible sources such as interest income. Many investors purify that share by donating it to charity; scholars differ on the details, so check with one you trust.
Do I need to pay Zakat on my Orexo AB A shares?
Yes, Zakat is generally due on stock holdings. The calculation depends on your school of thought (madhab) and whether you hold shares for trading or long-term investment. Use Mizaan's Zakat calculator to compute your obligation based on your specific madhab and holding intent.
